| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Dacisteine's primary mechanism of action is related to its mucolytic and antioxidant properties. As a derivative of cysteine, it contains a thiol group that can reduce disulfide bonds in mucus glycoproteins, thereby decreasing mucus viscosity and facilitating its clearance. This mucolytic action is beneficial in respiratory disorders characterized by excessive or thick mucus. Additionally, Dacisteine exhibits antioxidant properties, likely through its ability to scavenge reactive oxygen species (ROS) and replenish intracellular glutathione levels, a major endogenous antioxidant. Its hepatoprotective properties may be related to its antioxidant effects and its ability to modulate cellular redox balance. Dacisteine is used as a research tool to study these mechanisms and to explore potential therapeutic applications.
|
|---|---|
| ln Vitro |
In vitro studies have characterized Dacisteine's mucolytic and antioxidant activities. Its mucolytic activity is typically assessed by measuring its ability to reduce the viscosity of mucus samples or to break down disulfide bonds in mucin proteins. Its antioxidant activity is evaluated using cell-free assays, such as the DPPH radical scavenging assay or the ABTS assay, which measure the compound's ability to neutralize free radicals. In cell-based models, Dacisteine's ability to protect cells from oxidative stress induced by hydrogen peroxide or other oxidants is assessed. The compound's effects on glutathione levels and antioxidant enzyme activities are also measured in vitro. These studies confirm Dacisteine's potential as an antioxidant and mucolytic agent.
|
| ln Vivo |
Daxistan is a medication intended to treat or prevent disorders of the heart and brain brought on by platelet aggregation.
In vivo activity of Dacisteine has been studied in animal models of respiratory and liver diseases. In models of chronic bronchitis or other respiratory disorders, Dacisteine has been shown to reduce mucus viscosity and improve mucociliary clearance. Its hepatoprotective effects have been demonstrated in models of liver injury induced by toxins or oxidative stress. Dacisteine's antioxidant properties are believed to contribute to its protective effects in these models. However, detailed in vivo studies and specific protocols are not extensively described in the available literature. As a research compound, it is used to study the role of oxidative stress and mucolysis in various disease models. |
| Enzyme Assay |
Dacisteine, as N,S-diacetyl-L-cysteine, is a small molecule with a molecular weight of 205.23 g/mol. The in vitro enzyme/receptor binding assays for Dacisteine are not well-defined, as its mechanism of action is primarily related to its chemical properties (thiol group) rather than binding to a specific enzyme or receptor. Its mucolytic activity is based on its ability to reduce disulfide bonds, which is a chemical reaction rather than an enzyme-mediated process. Its antioxidant activity is based on its ability to scavenge free radicals and modulate redox balance. Therefore, standard enzyme inhibition or receptor binding assays are not typically performed for Dacisteine. Instead, its activity is assessed through functional assays that measure mucolysis, free radical scavenging, or cellular protection against oxidative stress.
|
| Cell Assay |
In vitro cell-based assays for Dacisteine are used to study its antioxidant and cytoprotective effects. In a typical assay, cells (e.g., hepatocytes, lung epithelial cells, or neuronal cells) are exposed to an oxidative stress inducer such as hydrogen peroxide or a toxin in the presence or absence of Dacisteine. Cell viability is then assessed using assays such as MTT or LDH release. The levels of intracellular reactive oxygen species (ROS) are measured using fluorescent probes like H2DCFDA. Glutathione levels and the activities of antioxidant enzymes such as superoxide dismutase (SOD) and catalase are also measured in cell lysates. These assays allow researchers to quantify the protective effects of Dacisteine against oxidative damage and to elucidate its mechanism of action at the cellular level.
|
| Animal Protocol |
In vivo animal experiments for Dacisteine are conducted to evaluate its mucolytic, antioxidant, and hepatoprotective effects. In a typical study for respiratory effects, animals (e.g., rats or guinea pigs) are exposed to irritants or infected with pathogens to induce mucus hypersecretion. Dacisteine is administered orally or by inhalation, and the viscosity and volume of tracheobronchial secretions are measured. For hepatoprotective studies, animals are treated with a hepatotoxic agent such as carbon tetrachloride or acetaminophen, followed by Dacisteine administration. Liver function is assessed by measuring serum markers such as ALT and AST, and liver tissue is examined for histopathological changes. These models are used to evaluate the therapeutic potential of Dacisteine in respiratory and liver diseases.
|
| ADME/Pharmacokinetics |
Dacisteine has a molecular weight of 205.23 g/mol and a molecular formula of C7H11NO4S. It is a white to off-white solid. Dacisteine is soluble in water and organic solvents, but specific solubility data is not detailed in the available literature. For storage, it is recommended to keep the compound at -20°C in a dry, dark environment. The compound is stable under normal storage conditions. Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized, but as a small, polar molecule, it is expected to be well-absorbed and rapidly cleared.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Dacisteine is not provided in standard product descriptions. As a derivative of cysteine, which is a naturally occurring amino acid, Dacisteine is expected to have low toxicity. However, comprehensive toxicological studies have not been extensively reported. In research settings, Dacisteine is used at concentrations that are effective for mucolysis and antioxidant protection without apparent cytotoxicity. As with all research chemicals, standard laboratory safety precautions should be followed when handling Dacisteine. Its safety profile would need to be further characterized for any potential therapeutic applications.
|
| References | |
| Additional Infomation |
Daxetine is an N-acyl-L-amino acid.
Dacisteine is a research compound and is not approved for any clinical or therapeutic use. It is a synthetic derivative of cysteine, specifically N,S-diacetyl-L-cysteine, that has been studied for its mucolytic, antioxidant, and hepatoprotective properties. Its mechanism of action is related to its ability to reduce disulfide bonds in mucus glycoproteins (mucolysis) and to scavenge reactive oxygen species and modulate glutathione levels (antioxidant). Dacisteine is a valuable compound for research into oxidative stress, metabolism, and therapeutic antioxidant strategies. It is used as a tool to study the mechanisms of mucolysis, antioxidant defense, and cellular protection against oxidative damage. As a research compound, it is not intended for human or veterinary use. |
| Molecular Formula |
C7H11NO4S
|
|---|---|
| Molecular Weight |
205.23
|
| Exact Mass |
205.041
|
| CAS # |
18725-37-6
|
| PubChem CID |
65690
|
| Appearance |
White to off-white solid powder
|
| Density |
1.314g/cm3
|
| Boiling Point |
446.8ºC at 760 mmHg
|
| Melting Point |
114-116°C
|
| Flash Point |
224ºC
|
| Vapour Pressure |
3.13E-09mmHg at 25°C
|
| Index of Refraction |
1.522
|
| LogP |
0.246
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
13
|
| Complexity |
229
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=O)N[C@@H](CSC(=O)C)C(=O)O
|
| InChi Key |
HSPYGHDTVQJUDE-LURJTMIESA-N
|
| InChi Code |
InChI=1S/C7H11NO4S/c1-4(9)8-6(7(11)12)3-13-5(2)10/h6H,3H2,1-2H3,(H,8,9)(H,11,12)/t6-/m0/s1
|
| Chemical Name |
(2R)-2-acetamido-3-acetylsulfanylpropanoic acid
|
| Synonyms |
DacisteinumDacisteine D-cysteine DcysteineDacisteina
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~1218.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.13 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8726 mL | 24.3629 mL | 48.7258 mL | |
| 5 mM | 0.9745 mL | 4.8726 mL | 9.7452 mL | |
| 10 mM | 0.4873 mL | 2.4363 mL | 4.8726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
